Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Suncor Energy Inc. (SU) Price & Performance

Cassava Sciences IncTrade
Suncor Energy Inc.Trade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Suncor Energy Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Suncor Energy Inc. trades at $60.99 (market cap $70.89B). The key difference: Suncor Energy Inc. is far larger — about 1334× Cassava Sciences Inc's market cap, and Suncor Energy Inc. pays a 2.78% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNASU
Market Cap
$53.14M$70.89B
Sector
HealthEnergy
52-Week High
$4.64$69.73
52-Week Low
$1.09$38.17
Enterprise Value
-$33.43M$79.02B
Dividend Yield
2.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

Suncor Energy Inc.

Suncor Energy (SU) trades at $61.04, down 0.38% on the day, with a bullish technical signal supported by moving averages. The company maintains solid fundamentals with a P/E of 16.37, net income margin of 11.62%, and consistent positive cash flow from operations ($12.78B in 2025). Recent quarterly earnings show a mixed pattern, beating expectations in Q3 and Q4 2025 but missing in Q1 2026, while Q2 2026 results are pending. The stock offers a dividend yield with a recent $0.60 per share payment announced for June 2026.

SU presents a compelling value opportunity with attractive valuation metrics (EV/EBITDA 6.91) and strong analyst support (74% buy ratings). Key opportunities include operational improvements, record production levels, and shareholder returns through dividends. Primary risks involve commodity price volatility, recent operational incidents like the Sarnia refinery fire, and broader energy sector headwinds from potential oil price declines and recession concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Suncor Energy Inc.

Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.

Read more on SU